𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Modification of 5-fluorouracil activity by high-dose methotrexate or leucovorin in advanced colorectal carcinoma

✍ Scribed by Sinnige, Harm A.M.; Sleijfer, Dirk Th.; de Vries, Elisabeth G.E.; Willemse, Pax H.B.; Mulder, Nanno H.

Book ID
123584649
Publisher
Elsevier Science
Year
1990
Weight
492 KB
Volume
26
Category
Article
ISSN
0277-5379

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sequential chemotherapy of advanced colo
Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil
✍ Solan, Andrew ;Vogl, Steven E. ;Kaplan, Barry H. ;Berenzweig, Marc ;Richard, Jos πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 313 KB

## Abstract Thirty patients with advanced measurable colorectal cancer were randomized to receive either methotrexate (MTX) 200 mg/m^2^ or 40 mg/m^2^, followed in four hours by 5‐fluorouracil (5‐FU) 600 mg/m^2^. Patients receiving the higher dose MTX were given leucovorin rescue 24 hours later. Eig

Hypocalcemia associated with 5-fluoroura
Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas
✍ Yuichiro Kido; Takeshi Okamura; Morimasa Tomikawa; Manabu Yamamoto; Morio Shirai πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 367 KB πŸ‘ 2 views

## BACKGROUND. The biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (Lv) has demonstrated significantly increased response rates in comparison with the use of 5-FU alone in patients with advanced colorectal carcinoma. However, the higher response rate of LV/5-FU may occur at the expen

Bimonthly high dose leucovorin and 5-flu
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma
✍ Karine Beerblock; Yves Rinaldi; Thierry AndrΓ©; Christophe Louvet; Eric Raymond; πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 2 views

with low dose LV. Based on these reports, a first-line Phase II study was performed in 101 patients with advanced colorectal carcinoma who were given a bimonthly